Bli medlem
Bli medlem

Du är här

2015-04-16

Actelion Pharmaceuticals Ltd: Actelion to discuss its specialty immunology pipeline compounds

Actelion Pharmaceuticals Ltd / Actelion to discuss its specialty immunology
pipeline compounds. Processed and transmitted by NASDAQ OMX Corporate
Solutions. The issuer is solely responsible for the content of this
announcement.
Dear member of the investment community

Actelion has announced that it is accelerating its clinical development
efforts in the field of immunological disorders. An investor conference
call&webcast will be held at 13.00 hrs, CEST to offer the opportunity to
discuss the rational for this strategic decision.

Date/Time
:

--------------------------------------------------------
| |
| 16 April 2015 13.00 hrs - 14.00 hrs Basel (CEST) |
| 12.00 hrs - 13.00 hrs UK (BST) |
| 07.00 a.m. - 08.00 a.m. US (EDT) |
--------------------------------------------------------

Conference Call Connect #:

Dial-in participants should start calling the number below 10-15 minutes
before the conference is due to start.

----------------------------------------
| |
| Dial: Europe: +41 (0) 44 580 00 77 |
| UK: +44 (0) 203 367 94 59 |
| US: +1 866 907 59 28 |
----------------------------------------

Participant's mode:

Listen-Only with possibility to open individual lines during Q&A session.
Participants will be asked for their Name and Company.

Webcast Access
:

Webcast participants should visit the Actelion
websitehttp://www.actelion.com10-15 minutes before the conference is due to
start.

Participant's mode:

Listen-Only

Webcast Replay:

The archived Investor Webcast will be available for replay
throughhttp://www.actelion.com/ approximately 60 minutes after the call has
ended.

Invitation PDF
http://hugin.info/131801/R/1911453/682012.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Globenewswire

HUG#1911453

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.